IL33 and COVID-19: Overall, our findings suggest that alarmin cytokines (IL-33, TSLP, and IL-25) could serve as potential therapeutic targets to modulate disease severity in COVID-19, and genetic variations influencing protein production can also protect against developing severe COVID-19.